Report workspace tools

NCT01486706COMPLETEDanonymous

Efficacy and Safety of Gabapentin in Treating Overactive Bladder

Sponsor

Source record

Michael E. Chua

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

Gabapentin, Solifenacin Succinate, Placebo drugs

Indication / condition

AI-normalized

Urinary Urgency

Intervention

Source record

Gabapentin, Solifenacin Succinate, Placebo drugs

Source & freshness

Source record

NCT ID

NCT01486706

Original source

ClinicalTrials.gov

Source last updated

Jan 02, 2017

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01486706

Title

Efficacy and Safety of Gabapentin in Treating Overactive Bladder

Sponsor

Michael E. Chua

Status

COMPLETED

Phase

PHASE2

Condition raw

Urinary Urgency, Urinary Frequency, Nocturia, Incontinence, Detrusor Uninhibited Activity, Quality of Life

Condition normalized

Urinary Urgency, Urinary Frequency, Nocturia, Incontinence, Detrusor Uninhibited Activity, Quality of Life

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Gabapentin, Solifenacin Succinate, Placebo drugs

Target normalized

Gabapentin, Solifenacin Succinate, Placebo drugs

Interventions

Gabapentin, Solifenacin Succinate, Placebo drugs

Public preview

Source record

Overactive bladder (OAB) syndrome as defined by International Continence Society is a pathological condition characterized by irritative symptoms: urinary urgency, with or without incontinence, urinary frequency and nocturia. The syndrome often seriously compromises the quality of life of the patients. The etiology of the OAB is considered multifactorial. Neural plasticity of bladder afferent pathways is one of the proposed mechanisms of OAB. The detrusor muscle itself has for many years been the target for drug treatment such as antimuscarinics. However, depression of detrusor contractility, may results in a reduced ability to empty the bladder and lead to some sympathetic adverse effects, which limits the treatment of OAB. Currently the focus of OAB treatment has changed to other bladder structures/mechanisms, such as afferent nerves and urothelial signaling as targets for intervention. C-fiber bladder afferents nerves may be critical for symptom generation in pathologic states such as OAB because these fibers demonstrate remarkable plasticity. Up-regulation of bladder C-fiber afferent nerve function may also play a role in urge incontinence, overactive bladder (OAB) and sensory urgency. The mechanism of Gabapentin's action for neuropathic pain has not been fully elucidated but is appears to have inhibitory activity on afferent C-fibers nerve activity; moreover, several studies had established the safety of Gabapentin in its treatment of different conditions. Due to the proposed mechanism, the investigators suggest that Gabapentin may be a new alternative for treating OAB.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account

Create a free account first, then unlock a single report, buy credits or subscribe.